 |
22 Products |  |
94 Diseases | | 22 Products |
|
46 Trials |  |
2720 News |  |
| «12...4567891011121314...2627» |
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
#PharmaMar se Desploma a Doble Dígito Tras Reportar un Incremento en los Gastos de I+D y Luego de Que Cayeran los Ingresos de #Zepzelca, su Medicamento Estrella. #RX_Securities Reduce sus Previsiones a Corto Plazo. https://t.co/utJOvFQQk4 #lurbinectedin #sclc #Ibex35 @JazzPharma (Twitter) - Jul 29, 2022
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Real-world (RW) outcomes of second-line (2L) small cell lung cancer (SCLC) patients treated with lurbinectedin (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_3241;
Lurbinectedin provides an additional treatment option for relapsed SCLC patients, including those with platinum-sensitive disease. Table: 1539P a % of overall b Assessed within 30 days prior to index c Platinum-based chemotherapy.
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Synthetic control arm (SCA) analysis of lurbinectedin compared to the standard of care (SoC) among patients with small cell lung cancer (SCLC) previously treated with platinum-based chemotherapy (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2938;
For patients with CTFI ≥90 days, the HR was 0.49 (0.33 - 0.73; p<0.001). Table: 1536P Baseline characteristics of SCLC patients in the SCA compared to the trial Conclusions These findings suggest potential benefit with initiation of lurbinectedin compared to the SoC in the post-platinum SCLC setting.
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical, Pan tumor: Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study @OncoAlert https://t.co/OUwKWW3AUB (Twitter) - Jul 28, 2022
- |||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open, Trial initiation date, Combination therapy: Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) (clinicaltrials.gov) - Jul 28, 2022
P3, N=705, Recruiting, Sponsor: PharmaMar
Table: 1536P Baseline characteristics of SCLC patients in the SCA compared to the trial Conclusions These findings suggest potential benefit with initiation of lurbinectedin compared to the SoC in the post-platinum SCLC setting. Not yet recruiting --> Recruiting | Initiation date: Apr 2022 --> Jul 2022
- || pioglitazone/metformin/dapagliflozin (BR3003) / Boryung Group
Trial completion: A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C. (clinicaltrials.gov) - Jul 27, 2022
P1, N=48, Completed, Sponsor: Boryung Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting | Initiation date: Apr 2022 --> Jul 2022 Recruiting --> Completed
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical, Pan tumor: Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study @OncoAlert @myESMO https://t.co/FMImp90eNN (Twitter) - Jul 25, 2022
- Kanarb (fimasartan) - Boryung Group, R / Pharm
Efficacy, safety and clinical experience of Fimasartan in Mexican patients with essential hypertension. (Amsterdam) - Jul 22, 2022 - Abstract #ESC2022ESC_5963;
Recruiting --> Completed Sponsored by Boryung Clinical
- Kanarb (fimasartan) - Boryung Group, R / Pharm
Fimasartan-based blood pressure control after acute cerebral ischemia: FABULOUS Study. (Amsterdam) - Jul 22, 2022 - Abstract #ESC2022ESC_5962;
Sponsored by Boryung Clinical Sponsored by Boryung Clinical
- Kanarb (fimasartan) - Boryung Group, R / Pharm
New clinical outcome of Fimasartan in the elderly and diabetic chronic kidney disease. (Amsterdam) - Jul 22, 2022 - Abstract #ESC2022ESC_5961;
Sponsored by Boryung Clinical Sponsored by Boryung Clinical
- Kanarb (fimasartan) - Boryung Group, R / Pharm
New clinical outcomes of Fimasartan (Amsterdam) - Jul 22, 2022 - Abstract #ESC2022ESC_5960;
Sponsored by Boryung Clinical Sponsored by Boryung Clinical review on the effectiveness and safety of fimasartan a new drug for hypertension.
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: #PharmaMar reported that Chinese health authorities approve #Lurbinectedin for urgent clinical use $PHM https://t.co/ANQLYg3CHH (Twitter) - Jul 19, 2022
- || Zepzelca (lurbinectedin) / PharmaMar, Jazz
More of Lurbi, from #ASCO22 #cancerDeMama #breastcancer #lurbinectedina #lurbinectedin https://t.co/hOfZMRN356 #pharmamar #zepzelca (Twitter) - Jul 18, 2022
- || SLC022 / Solace, Zepzelca (lurbinectedin) / PharmaMar, Jazz
https://t.co/Lscmei3YNw #lurbinectedin #sclc #pharmamar #ASCO22 #ESMO2022 #IASLC2022 #worldconferenceonlungcancer (Twitter) - Jul 18, 2022
- || BR1018 / Boryung Group
New P1 trial: A Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult Subjects (clinicaltrials.gov) - Jul 15, 2022
P1, N=36, Recruiting, Sponsor: Boryung Pharmaceutical Co., Ltd
- || Zepzelca (lurbinectedin) / PharmaMar, Jazz
thats what happen when you keep raving about Lurbinectedin 🤣 (Twitter) - Jul 14, 2022
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Pan tumor: ⭐️Lurbinectedin approved for small cell #lungcancer is active in many tumor types. ✅ Lurbinectedin activity in neuroendocrine tumours 👉🏼phase II basket study now published in European Journal of Cancer @OncoAlert https://t.co/nGgrzMWEY1 (Twitter) - Jul 14, 2022
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical, Pan tumor: Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study published in European Journal of Cancer @OncoAlert https://t.co/IBNTMfRtkr (Twitter) - Jul 14, 2022
- | Zepzelca (lurbinectedin) / PharmaMar, Jazz
Journal: Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study. (Pubmed Central) - Jul 13, 2022
According to our very small sample size, we hypothesize that baseline TAMs and regulatory T cells are associated with survival. Lurbinectedin seems to inhibit conversion of TAMs to M2 phenotype in humans.
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
fyi 👇https://t.co/L5iTYVIcUu @LealTiciana @PazAresLab @dr_ponce_aix @StephenVLiu @sands_jacob @LaurenByersMD @VivekSubbiah @Tony_Calles #lurbinectedin @mesothelioma @curemeso @CancerAlliance @PhrmMar (Twitter) - Jul 12, 2022
- |||||| berzosertib (M6620) / EMD Serono, Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical, P1/2 data, Combination therapy: Another ongoing phase I/II trial seeks to study the efficacy of berzosertib, an ATR kinase inhibitor, in combination with lurbinectedin for SCLC and high-grade neuroendocrine cancers (NCT04802174). (Twitter) - Jul 10, 2022
P1/2
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz, irinotecan / Generic mfg.
P1/2 data, Combination therapy: Another phase I/II study (NCT02611024) is evaluating lurbinectedin in combination with irinotecan and includes a gastroenteropancreatic NETs cohort. (Twitter) - Jul 10, 2022
P1/2
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: The ongoing EMERGE-201 trial (NCT05126433) has included a cohort of large cell neuroendocrine carcinoma patients to be treated with lurbinectedin as a single agent. (Twitter) - Jul 10, 2022
P2
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
For instance, large cell neuroendocrine carcinoma or higher grade 3 NETs, where the Ki-67 is in the range 30–55% might better mirror the small cell lung cancer population, where lurbinectedin has shown activity @ADesaiMD (Twitter) - Jul 10, 2022
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Biomarker, Clinical: Further pharmacogenomic and molecular analysis may help to define the NET population that could obtain benefit from lurbinectedin therapy. (Twitter) - Jul 10, 2022
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical, Combination therapy, Monotherapy: Further development of lurbinectedin in NETs could be warranted as monotherapy or combination therapy although it should be performed in a selected NET population. (Twitter) - Jul 10, 2022
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: ⭐️Lurbinectedin in patients with pretreated neuroendocrine tumours @myESMO European Journal of Cancer @OncoAlert https://t.co/WRIpqiz6kw (Twitter) - Jul 10, 2022
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study 5/5 @CCR_AACR https://t.co/EHkVlEVBhY (Twitter) - Jul 10, 2022
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical, Pan tumor: Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial 4/5 @TheLancetOncol https://t.co/KI8Z6znfIA (Twitter) - Jul 10, 2022
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Lurbinectedin ( marine anti-cancer drug) is a selective inhibitor of oncogenic transcription that binds preferentially to guanines located in the GC-rich regulatory areas of DNA gene promoters. It is active in small cell lung & many other tumor types 3/5 https://t.co/GFlJVJEBw0 (Twitter) - Jul 10, 2022
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical, Pan tumor: 🚨Delighted to share our paper 🔥 Hot off the press in European Journal of Cancer @myESMO ✅Lurbinectedin in patients with pretreated neuroendocrine tumours: Phase II basket study ✅Lurbinectedin = marine anti-cancer agent 🌊🪸 1/5 @OncoAlert @cdanicas https://t.co/GFlJVJEBw0 (Twitter) - Jul 10, 2022
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Excuse me please Dr. one question, Were data on the use of lurbinectedin in mesothelioma shown at the congress? (Twitter) - Jul 10, 2022
- |||| Keytruda (pembrolizumab) / Merck (MSD), Zepzelca (lurbinectedin) / PharmaMar, Jazz
Dr. @LealTiciana highlights options in relapsed #SCLC including lurbinectedin as 2L alone (ATLANTIS) or with pembrolizumab (LUPER, @Tony_Calles). Nice to see new options in development at #DAVAHawaiiLung (Twitter) - Jul 7, 2022
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Great overview of lurbinectedin in ES-SCLC by @LealTiciana and subgroups with preferential benefit from ATLANTIS study @OMIonc (Twitter) - Jul 7, 2022
- || Zepzelca (lurbinectedin) / PharmaMar, Jazz
P2 data, Journal: Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. (Pubmed Central) - Jul 6, 2022
Lurbinectedin was active in the treatment of relapsed ES and had a manageable safety profile. Lurbinectedin could represent a valuable addition to therapies for ES, and is currently being evaluated in combination with irinotecan in advanced ES in a phase Ib/II trial.
- | Aplidin (plitidepsin) / PharmaMar, Roche
Y la plitidepsina curando “solo” a unos pocos privilegiados y/o afortunados que entran en el ensayo Neptuno. Bravo por la @AEMPSGOB @EMA_News y @FDAenEspanol gracias @chuslamas muchas gracias!!! 👏🏻👏🏻👏🏻💪🏻💪🏻. (Twitter) - Jul 2, 2022
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study https://t.co/GG4kbYYyVi (Twitter) - Jul 2, 2022
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: It is always challenging to conduct studies in rare diseases like sarcoma 👉Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma @CCR_AACR @OncoAlert @AACR https://t.co/UygXtn071p (Twitter) - Jul 2, 2022
- || Aplidin (plitidepsin) / PharmaMar, Roche
Review, Journal: Marine Cyclic Peptides: Antimicrobial Activity and Synthetic Strategies. (Pubmed Central) - Jun 30, 2022
Marine cyclic peptides are also interesting models for molecular modifications and/or total synthesis to obtain more potent compounds, with improved properties and in higher quantity. Solid-phase Fmoc- and Boc-protection chemistry is the major synthetic strategy to obtain marine cyclic peptides with antimicrobial properties, and key examples are presented guiding microbiologist and medicinal chemists to the discovery of new antimicrobial drug candidates from marine sources.
- || Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial completion date, Trial primary completion date, Real-world evidence, Real-world: EMERGE 402: To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Jun 30, 2022
P=N/A, N=300, Recruiting, Sponsor: Jazz Pharmaceuticals
Solid-phase Fmoc- and Boc-protection chemistry is the major synthetic strategy to obtain marine cyclic peptides with antimicrobial properties, and key examples are presented guiding microbiologist and medicinal chemists to the discovery of new antimicrobial drug candidates from marine sources. Trial completion date: Sep 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Jun 2024
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open, Real-world evidence, Real-world effectiveness, Real-world: LURBICLIN: RW Effectiveness of Lurbinectedin in Extensive Stage SCLC (clinicaltrials.gov) - Jun 30, 2022
P=N/A, N=200, Recruiting, Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Trial completion date: Sep 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Jun 2024 Not yet recruiting --> Recruiting
- | Aplidin (plitidepsin) / PharmaMar, Roche
Y el Aplidin curando, pero solo a unos pocos privilegiados… bravo 👏🏻 👏🏻👏🏻 @AEMPSGOB @EMA_News y @FDAenEspanol (Twitter) - Jun 29, 2022
- || Blenrep (belantamab mafodotin) / GSK, Aplidin (plitidepsin) / PharmaMar, Roche
Review, Journal: Multiple Myeloma: Possible Cure from the Sea. (Pubmed Central) - Jun 25, 2022
In addition, other natural products have been identified from marine organisms, tested for their possible anticancer properties, and are in preclinical or clinical trials for MM, including cytarabine, a compound in use for leukaemia treatment...Active compounds belong to different chemical classes, from cyclic peptides to alkaloids, highlighting the importance of screening the plethora of compounds produced by marine organisms. In this review, we summarise the current state of art of MM therapies focusing on the marine natural product emerging roles.
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
EMERGE 402: Preliminary Real-world Characteristics and Safety of Lurbinectedin in Patients With Small-cell Lung Cancer (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1874;
The observed real-world safety profile of lurbinectedin is generally consistent with the phase 2 study, with no new safety signals. EMERGE 402 continues to enroll patients to further assess the effectiveness and safety of lurbinectedin, and updated data analyzing a larger sample size will be reported at the meeting.
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Phase I Study of Palliative Radiotherapy with Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1583;
P1
This study was activated in March 2022 with an accrual goal of 11 patients each to cohort 1 and cohort 2 (n=22 total). This study is funded by Jazz Pharmaceuticals.
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Characterization of Real-World Use of Lurbinectedin in Adult Small Cell Lung Cancer Patients in the United States (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1576;
Lurbinectedin use to date reflects per-label treatment in metastatic SCLC patients who previously received platinum-based chemotherapy. Lurbinectedin approval represents a new therapy in the treatment landscape for 2LT+ SCLC patients.
- Zepzelca (lurbinectedin) / PharmaMar, Jazz, Tecentriq (atezolizumab) / Roche
IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1328;
P3
Independent review facility-assessed progression-free survival (PFS) per RECIST 1.1 and OS are the co-primary endpoints. Secondary endpoints include investigator-assessed PFS, ORR, duration of response, quality of life and safety/tolerability.
- || Zepzelca (lurbinectedin) / PharmaMar, Jazz, Aplidin (plitidepsin) / PharmaMar, Roche
https://t.co/KFO5kVxoW3 #plitidepsin + #lurbinectedin #pharmamar against Multiple Myeloma 👏🏻💪🏻 @PhrmMar @EMA_News @FDA @AEMPSGOB @sanidadgob (Twitter) - Jun 16, 2022
- || Zepzelca (lurbinectedin) / PharmaMar, Jazz
Too bad CodeBreaK100 is like a year old now, that would have been a good one. Or lurbinectedin (the ATLANTIS trial failed), but PM1183-B-005-14 trial is also old. CM816? Nothing else I can think of. (Twitter) - Jun 11, 2022
- || pioglitazone/metformin/dapagliflozin (BR3003) / Boryung Group
New P1 trial: A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C. (clinicaltrials.gov) - Jun 8, 2022
P1, N=46, Recruiting, Sponsor: Boryung Pharmaceutical Co., Ltd